{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT03632291",
      "orgStudyIdInfo": {
        "id": "UBP-A107-IgE"
      },
      "organization": {
        "fullName": "United BioPharma",
        "class": "INDUSTRY"
      },
      "briefTitle": "Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients",
      "officialTitle": "A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of UB-221 as an Add-on Therapy in Patients With Chronic Spontaneous Urticaria"
    },
    "statusModule": {
      "statusVerifiedDate": "2022-05",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2019-04-09",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2021-01-19",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2021-01-19",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2018-08-13",
      "studyFirstSubmitQcDate": "2018-08-13",
      "studyFirstPostDateStruct": {
        "date": "2018-08-15",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2022-05-12",
      "lastUpdatePostDateStruct": {
        "date": "2022-05-13",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "United BioPharma",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "isFdaRegulatedDrug": false,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of UB-221 as an add-on therapy in patients with Chronic Spontaneous Urticaria.",
      "detailedDescription": "This is a phase I, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of UB-221 as an add-on therapy in patients with Chronic Spontaneous Urticaria."
    },
    "conditionsModule": {
      "conditions": [
        "Urticaria Chronic"
      ],
      "keywords": [
        "UB-221",
        "anti-IgE monoclonal antibody",
        "chronic spontaneous urticaria (CSU)"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "designInfo": {
        "allocation": "NON_RANDOMIZED",
        "interventionModel": "SEQUENTIAL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 15,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "UB-221 (0.2 mg/kg)",
          "type": "EXPERIMENTAL",
          "description": "Intravenous infusion",
          "interventionNames": [
            "Biological: UB-221"
          ]
        },
        {
          "label": "UB-221 (0.6 mg/kg)",
          "type": "EXPERIMENTAL",
          "description": "Intravenous infusion",
          "interventionNames": [
            "Biological: UB-221"
          ]
        },
        {
          "label": "UB-221 (2 mg/kg)",
          "type": "EXPERIMENTAL",
          "description": "Intravenous infusion",
          "interventionNames": [
            "Biological: UB-221"
          ]
        },
        {
          "label": "UB-221 (6 mg/kg)",
          "type": "EXPERIMENTAL",
          "description": "Intravenous infusion",
          "interventionNames": [
            "Biological: UB-221"
          ]
        },
        {
          "label": "UB-221 (10 mg/kg)",
          "type": "EXPERIMENTAL",
          "description": "Intravenous infusion",
          "interventionNames": [
            "Biological: UB-221"
          ]
        }
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "UB-221",
          "description": "UB-221 (75 mg/ml)",
          "armGroupLabels": [
            "UB-221 (0.2 mg/kg)",
            "UB-221 (0.6 mg/kg)",
            "UB-221 (10 mg/kg)",
            "UB-221 (2 mg/kg)",
            "UB-221 (6 mg/kg)"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Adverse event incidence",
          "description": "from the baseline to day 15 after IP infusion",
          "timeFrame": "15 days"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects with age between 20 to 65 years old (inclusive).\n* Subjects who are able and willing to provide the informed consent.\n* Male subjects with body weight of 50 kilogram (kg) or above; female subjects body weight of 45 kilogram (kg) or above.\n* Subjects diagnosed with chronic spontaneous urticaria (CSU).\n\nExclusion Criteria:\n\n* History of significant diseases (other than CSU) or major clinical conditions by the investigator's judgment, such as auto-immune disease or psychiatric and behavioral conditions from which the investigator considers the subject is not suitable to participate in this study.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "20 Years",
      "maximumAge": "75 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "locations": [
        {
          "facility": "Kaohsiung Chang Gung Memorial Hospital",
          "city": "Kaohsiung City",
          "zip": "83301",
          "country": "Taiwan",
          "geoPoint": {
            "lat": 22.61626,
            "lon": 120.31333
          }
        },
        {
          "facility": "National Taiwan University Hospital",
          "city": "Taipei",
          "zip": "100",
          "country": "Taiwan",
          "geoPoint": {
            "lat": 25.05306,
            "lon": 121.52639
          }
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D000080223",
          "term": "Chronic Urticaria"
        }
      ],
      "ancestors": [
        {
          "id": "D014581",
          "term": "Urticaria"
        },
        {
          "id": "D017445",
          "term": "Skin Diseases, Vascular"
        },
        {
          "id": "D012871",
          "term": "Skin Diseases"
        },
        {
          "id": "D017437",
          "term": "Skin and Connective Tissue Diseases"
        },
        {
          "id": "D006969",
          "term": "Hypersensitivity, Immediate"
        },
        {
          "id": "D006967",
          "term": "Hypersensitivity"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        },
        {
          "id": "D002908",
          "term": "Chronic Disease"
        },
        {
          "id": "D020969",
          "term": "Disease Attributes"
        },
        {
          "id": "D010335",
          "term": "Pathologic Processes"
        },
        {
          "id": "D013568",
          "term": "Pathological Conditions, Signs and Symptoms"
        }
      ]
    }
  },
  "hasResults": false
}